AbbVie closes its $10.9 billion Apogee Therapeutics acquisition, adding a late-stage immunology pipeline

AbbVie announced the closing of its acquisition of Apogee Therapeutics, a deal valued at about $10.9 billion, or $135.11 per share, adding a late-stage immunology and respiratory pipeline to its portfolio and keeping analysts' buy ratings intact. The transaction was completed in early September 2026, finalising a multi-year negotiation process.

Alongside the closing, Apogee's outstanding equity awards converted to cash under the merger agreement, and the chief executive's stock and options were paid out on that mechanical basis. Apogee's chief financial officer filed an identical same-day disclosure, which is what a standard change-of-control conversion looks like rather than a discretionary decision to sell.

The acquisition expands AbbVie's presence in immunology and respiratory disease, where Apogee has been developing candidates for atopic dermatitis and asthma. By integrating Apogee's pipeline, AbbVie aims to diversify its revenue streams and accelerate the launch of new treatments.

Investors will watch AbbVie's integration progress and the impact on its earnings outlook, while market participants may assess whether the premium paid justifies the long-term value of Apogee's assets. The equity conversion at close is a routine feature of a change of control rather than a signal about the underlying assets.

Related Stocks

• ABBV
• APGE